Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1

Aim. Evaluate the one­year results and clinical outcomes of a multi­center randomized clinical trial FRIDOM1.

Material and methods. The study FRIDOM1 was conducted in 11 clinical centers of the Russian Federation in the period 2014­2016. The study included 382 patients with acute ST­elevated myocardial infarction (STEMI), who were randomly divided into the Fortelyzin® and Metalyse®. Thrombolysis was accompanied by anticoagulant and dual antiplatelet therapy followed by percutaneous coronary intervention (PCI). One­year patient status, all­cause mortality, including cardiovascular diseases (CVD), hospitalization, and one­year survival were assessed by telephone contact.

Results. The one­year patient status was determined in 186 out of 191 (97,4%) in the Fortelyzin® group and in 185 out of 191 (96,9%) patients in the Metalyse® group. One­year all­cause mortality was 5,9% and 6,5% in the Fortelyzin® and Metalyse® groups, respectively (p=0,83; OR 0,91; 95% CI — 0,42­1,98). One­year mortality from CVD in the Fortelyzin® group is 5,4%, in the Metalyse® group — 6,5% (p=0,67; OR 0,83; 95% CI — 0,37­1,83). All­cause mortality between 30 days and 1 year in the Fortelyzin® group was in 2,2% of patients, CVD — in 1,6%, in the group of Metalise® mortality was in 2,7% of patients (all — CVD). One­year survival was 94,1% and 93,5% in the Fortelyzin® and Metalyse® groups, respectively.

Conclusion. The one­year results of the FRIDOM1 study showed the efficacy and safety of a single bolus administration of Fortelyzin® as part of a pharmaco­invasive strategy for treating patients with STEMI, as well as clinical outcomes that are comparable with Metalyse®, including high survival rates and low CVD mortality.

1. Clinical guidelines Diagnosis and management of ST-segment elevation myocardial infarction // Kardiologicheskij Vestnik. 2014, № 4: 5-60.

2. Work group ESC. 2017 ESC Guidelines for themanagtment of acutemyocardial infarction in patients presenting with ST-segment elevation Rus J Cardiol 2017; 23(5): 103-158

3. Markov V.A., Duplyakov D.V., Konstantinov S.L., Klein H.V., Aksentiev S.B., Platonov D. Ju., Vyashlov Eu.V., Ponomarev Ed.A., Rabinovich R.M., Makarov Eu.L., Kulibaba E.V., Krickaya O.V., Baranov Eu.A., Talibov O.B., Gerasimetc E.A. FORTELYZIN® VERSUS METALYSE® IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: RESULTS OF MULTICENTER RANDOMIZED trial FRIDOM 1.

4. Armstrong P.W., Gershlick A.H., Goldstein P. et al. Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction // N Engl J Med 2013; 368:1379–87.

5. Peter R. Sinnaeve, Paul W. Armstrong, Anthony H. Gershlick Patrick Goldstein et al. ST–Segment-Elevation Myocardial Infarction Patients Randomized to a Pharmaco-Invasive Strategy or Primary Percutaneous Coronary Intervention. Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-Year Mortality Follow-Up // Circulation. 2014;130:1139–1145.

6. Инструкция по медицинскому применению препарата Фортелизин®.

7. Markov V.A., Vyshlov E.V., Karpov R.S. Coronary reperfusion in ST elevation myocardial infarction: problems and solutions. Russ J Cardiol 2015, № 1 (117): 53-58.

8. Fedorov A.V., Belova L.P. The principles of organization of aid and pre-hospital thrombolysis patients with acute coronary syndrome in the Chuvash Republic. Emergency medical care. 2017;18(3):39-43.

9. Mazur E.S., Rabinovich R.M., Mazur V.V., Kuznetsova N.S. et al. The results of use of new native thrombolytic in clinical practice // Rational Pharmacotherapy in Cardiology 2016; 12(2):160-165.

10. Vishlov E.V., Alekseeva Ya.V., Gerasimets E.A., Markov V.A. Experimental and clinical studies of staphylokinase and Fortelyzin®. Kardiologija 2017; 2:57-61.

11. Khripun A.V., Malevanny M.V., Kulikovskikh Ya.V., Kastanyan A.A. In-patient outcomes of pharmacoinvasive reperfusion strategy for ST elevation // Rus J Cardiol 2016, 3(131): 99-104.

12. Valeriy B. Kostogryz Results of Hospital Use of Recombinant Non-Immunogenic Staphylokinase in Patients with ST-Elevated Myocardial Infarction 2017, 13(1), 51-54.